MiMedx Group (NASDAQ:MDXG) Stock Price Up 7% – Still a Buy?

MiMedx Group, Inc (NASDAQ:MDXG) shares were up 7% during mid-day trading on Friday . The company traded as high as $3.59 and last traded at $3.5950. Approximately 747,028 shares were traded during mid-day trading, a decline of 38% from the average daily volume of 1,212,878 shares. The stock had previously closed at $3.36.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on MDXG shares. Lake Street Capital cut their target price on MiMedx Group from $12.00 to $10.00 and set a “buy” rating on the stock in a research report on Tuesday, January 20th. Craig Hallum cut their target price on MiMedx Group from $10.00 to $7.00 and set a “buy” rating on the stock in a research report on Friday, April 17th. Citizens Jmp cut their target price on MiMedx Group from $7.00 to $6.00 and set a “market outperform” rating on the stock in a research report on Thursday. Cantor Fitzgerald cut their target price on MiMedx Group from $12.00 to $8.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 17th. Finally, Citigroup started coverage on MiMedx Group in a research report on Monday, February 23rd. They issued a “market outperform” rating on the stock. Six analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, MiMedx Group presently has an average rating of “Moderate Buy” and a consensus target price of $8.50.

MiMedx Group Stock Performance

The company has a current ratio of 4.32, a quick ratio of 3.92 and a debt-to-equity ratio of 0.06. The company has a 50-day moving average of $4.12 and a 200-day moving average of $5.63. The firm has a market capitalization of $543.02 million, a price-to-earnings ratio of 18.13 and a beta of 1.65.

MiMedx Group (NASDAQ:MDXG) last issued its earnings results on Wednesday, April 29th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.02. MiMedx Group had a return on equity of 21.15% and a net margin of 7.88%.The firm had revenue of $58.99 million for the quarter, compared to analyst estimates of $65.80 million. On average, equities research analysts forecast that MiMedx Group, Inc will post 0.08 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Hsbc Holdings PLC grew its stake in shares of MiMedx Group by 17.1% in the first quarter. Hsbc Holdings PLC now owns 161,510 shares of the company’s stock worth $627,000 after purchasing an additional 23,528 shares in the last quarter. Isthmus Partners LLC grew its stake in shares of MiMedx Group by 9.9% in the first quarter. Isthmus Partners LLC now owns 482,127 shares of the company’s stock worth $1,904,000 after purchasing an additional 43,395 shares in the last quarter. Y Intercept Hong Kong Ltd bought a new position in shares of MiMedx Group in the first quarter worth $65,000. Strs Ohio grew its stake in shares of MiMedx Group by 50.0% in the first quarter. Strs Ohio now owns 138,900 shares of the company’s stock worth $549,000 after purchasing an additional 46,300 shares in the last quarter. Finally, OP Asset Management Ltd bought a new position in shares of MiMedx Group in the first quarter worth $2,406,000. Institutional investors own 79.15% of the company’s stock.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.